The myth of the biotech revolution: An assessment of technological, clinical and organisational change

被引:135
作者
Hopkins, Michael M.
Martin, Paul A.
Nightingale, Paul [1 ]
Kraft, Alison
Mahdi, Surya
机构
[1] Univ Sussex, Freeman Ctr, SPRU, Brighton BN1 9QE, E Sussex, England
[2] Univ Nottingham, Inst Study Genet Biorisks & Soc, Nottingham NG7 2RD, England
基金
英国经济与社会研究理事会;
关键词
biotechnology; revolution; innovation; policy;
D O I
10.1016/j.respol.2007.02.013
中图分类号
C93 [管理学];
学科分类号
12 ; 1201 ; 1202 ; 120202 ;
摘要
This paper argues that despite being widely promoted by academics and consultants, the empirical evidence does not support the existence of a biotech revolution. Nor does the data support the widely held expectations that biotechnology is having a revolutionary impact on healthcare or economic development. The revolutionary model is therefore a misleading basis for policy making as it over-estimates the speed and extent of any changes in productivity or the quality of therapeutics. Instead, the evidence suggests biotechnology is following a well-established incremental pattern of technological change and 'creative accumulation' that builds upon, rather than disrupts, previous drug development heuristics. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:566 / 589
页数:24
相关论文
共 134 条
[1]  
Angell MarciaM.D., 2004, The Truth About Drug Companies: How They Deceive Us and What To Do About It
[2]  
[Anonymous], 2001, REVOLUTION R D GENOM
[3]  
[Anonymous], 1992, CODE CODESCI SOCIA
[4]  
[Anonymous], EXPLORING BLACK BOX
[5]  
[Anonymous], 1995, BICYCLES BAKELITE BU
[6]  
ARIENS EJ, 1964, MED CHEM SERIES, pR16
[7]  
Arnst C, 2005, BUS WEEK, P41
[8]  
ARUNDEL A, 2004, IMPACT BIOTECHNOLOGY
[9]   The new genetics - The new genetics in clinical practice [J].
Bell, J .
BMJ-BRITISH MEDICAL JOURNAL, 1998, 316 (7131) :618-620
[10]   The double helix in clinical practice [J].
Bell, JI .
NATURE, 2003, 421 (6921) :414-416